Laryngeal Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LRY018 MIFTS: 51	Laryngeal Squamous Cell Carcinoma Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Laryngeal Squamous Cell Carcinoma

MalaCards integrated aliases for Laryngeal Squamous Cell Carcinoma:

Name: Laryngeal Squamous Cell Carcinoma ¹¹ ⁵³ ¹⁴ ¹⁶

Squamous Cell Carcinoma of Head and Neck ⁴³

Squamous Cell Carcinoma of the Larynx ⁵⁸

Epidermoid Carcinoma of the Larynx ¹¹

Squamous Cell Carcinoma of Larynx ¹¹

Characteristics:

Prevelance:

Squamous Cell Carcinoma of the Larynx: 1-9/100000 (Europe) ⁵⁸

Age Of Onset:

Squamous Cell Carcinoma of the Larynx: Adolescent,Adult,Childhood,Elderly ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases Skin diseases Oral diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:2876

MeSH ⁴³ D000077195

NCIt ⁴⁹ C4044

SNOMED-CT ⁶⁸ 707358000

Orphanet ⁵⁸ ORPHA494550

EFO ¹⁶ EFO_0006352

UMLS ⁷¹ C0280324

Sources

Summaries for Laryngeal Squamous Cell Carcinoma

Orphanet: ⁵⁸ A rare head and neck tumor characterized by a malignant epithelial neoplasm with evidence of squamous differentiation, most commonly located in the supraglottis or glottis. The tumor can spread directly to adjacent structures or metastasize via lymphatic and blood vessels to regional lymph nodes, or lung, liver, and bones, respectively. Primary risk factors are tobacco smoking and (to a lesser extent) alcohol consumption. Patients may present with hoarseness, dyspnea, stridor, dysphagia, hemoptysis, or odynophagia.

MalaCards based summary: Laryngeal Squamous Cell Carcinoma, also known as squamous cell carcinoma of head and neck, is related to laryngeal benign neoplasm and larynx cancer. An important gene associated with Laryngeal Squamous Cell Carcinoma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are TNFR1 Pathway and Endometrial cancer. The drugs Ethanol and Petrolatum have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and liver, and related phenotypes are neoplasm and no phenotypic analysis

Disease Ontology: ¹¹ A laryngeal carcinoma that has material basis in squamous cells.

Sources

Related Diseases for Laryngeal Squamous Cell Carcinoma

Diseases related to Laryngeal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)

#	Related Disease	Score	Top Affiliating Genes
1	laryngeal benign neoplasm	32.8	TP53 EGFR CDKN2A CCND1
2	larynx cancer	32.6	TP53 MIR21 EGFR CCND1 BCL2
3	head and neck cancer	32.0	TP53 PTEN MIR21 EGFR CDKN2A CCND1
4	papilloma	31.9	TP53 PTEN EGFR CDKN2A CCND1 BCL2
5	hypopharynx cancer	31.7	TP53 EGFR CDKN2A CCND1 BCL2
6	squamous cell carcinoma	31.5	TP53 TNFRSF10B PTEN NEAT1 MALAT1 ING1
7	keratinizing squamous cell carcinoma	31.4	TP53 EGFR CDKN2A
8	carcinosarcoma	31.2	TP53 PTEN EGFR CDKN2A
9	suppression of tumorigenicity 12	31.2	TP53 PTEN EGFR CDKN2A
10	lip and oral cavity cancer	31.2	TP53 MIR21 EGFR CDKN2A CCND1
11	gastroesophageal reflux	31.2	TP53 EGFR CCND1 BCL2
12	squamous cell carcinoma, head and neck	31.1	TP53 TNFRSF10B PTEN MIR21 ING1 HOTAIR
13	actinic keratosis	31.1	TP53 EGFR CDKN2A BCL2
14	b-cell lymphoma	31.0	TP53 MALAT1 HOTAIR CDKN2A CCND1 BCL2
15	lymphoma	31.0	TP53 EGFR CDKN2A CCND1 BCL2
16	neurofibroma	31.0	TP53 PTEN EGFR CDKN2A
17	chronic lymphocytic leukemia/small lymphocytic lymphoma	31.0	TP53 CCND1 BCL2
18	basal cell nevus syndrome	31.0	TP53 PTEN CCND1 BCL2
19	keratoacanthoma	31.0	TP53 EGFR BCL2
20	paraganglioma	31.0	EGFR CDKN2A CCND1 BCL2
21	human papillomavirus infectious disease	30.9	TP53 PTEN MIR21 EGFR CDKN2A CCND1
22	oropharynx cancer	30.9	TP53 PTEN MIR21 EGFR CDKN2A CCND1
23	salivary gland carcinoma	30.9	TP53 EGFR CDKN2A
24	glottis squamous cell carcinoma	30.9	PTEN EGFR
25	verrucous carcinoma	30.9	TP53 EGFR CDKN2A
26	leukemia, chronic lymphocytic	30.9	TP53 PTEN NEAT1 MIR21 EGFR CDKN2A
27	suppressor of tumorigenicity 3	30.9	TP53 CDKN2A BCL2
28	mixed cell type cancer	30.9	TP53 PTEN EGFR CDKN2A
29	keratosis	30.9	TP53 EGFR CDKN2A BCL2
30	liposarcoma	30.9	TP53 PTEN CDKN2A CCND1 BCL2
31	leiomyosarcoma	30.8	TP53 CDKN2A CCND1 BCL2
32	malignant peripheral nerve sheath tumor	30.8	TP53 EGFR CDKN2A
33	adenoid cystic carcinoma	30.8	TP53 PTEN EGFR CDKN2A CCND1 BCL2
34	small cell carcinoma	30.8	TP53 PTEN EGFR
35	thymoma	30.8	TP53 EGFR CDKN2A BCL2
36	peripheral nervous system disease	30.8	TP53 PTEN MIR21 EGFR CDKN2A CCND1
37	thyroid gland follicular carcinoma	30.8	TP53 PTEN CCND1
38	esophagus adenocarcinoma	30.7	TP53 MIR21 EGFR CDKN2A CCND1
39	colonic benign neoplasm	30.7	TP53 PTEN MIR21 EGFR CDKN2A CCND1
40	skin carcinoma	30.7	TP53 PTEN MIR21 EGFR CDKN2A CCND1
41	gastrointestinal stromal tumor	30.7	TP53 PTEN HOTAIR EGFR CDKN2A CCND1
42	small cell cancer of the lung	30.7	TP53 PTEN MIR21 MALAT1 HOTAIR EGFR
43	cervix carcinoma	30.7	TP53 PTEN MIR21 HOXA11-AS EGFR CDKN2A
44	skin disease	30.6	TP53 PTEN MIR21 EGFR CDKN2A CCND1
45	basal cell carcinoma	30.6	TP53 PTEN EGFR CDKN2B-AS1 CDKN2A BCL2
46	lung squamous cell carcinoma	30.6	TP53 PTEN EGFR CDKN2A CCAT1
47	intrahepatic cholangiocarcinoma	30.6	TP53 EGFR CCAT1
48	breast adenocarcinoma	30.6	TP53 PTEN H19 EGFR CDKN2A CCND1
49	adenocarcinoma	30.6	TP53 PTEN MALAT1 H19 EGFR CDKN2A
50	skin squamous cell carcinoma	30.5	TP53 PTEN MIR21 HOTAIR EGFR CDKN2A

Graphical network of the top 20 diseases related to Laryngeal Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Laryngeal Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Laryngeal Squamous Cell Carcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.56	BCL2 CCND1 CDKN2A EGFR ING1 PTEN
2	no phenotypic analysis	MP:0003012	9.17	CDKN2A EGFR HOTAIR HOXA11-AS MALAT1 TNFRSF10B

Sources

Drugs & Therapeutics for Laryngeal Squamous Cell Carcinoma

Drugs for Laryngeal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 345)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ethanol

Approved

Phase 4

64-17-5

702

Petrolatum

Approved, Investigational

Phase 4

8009-03-8

Mometasone furoate

Approved, Investigational, Vet_approved

Phase 4

83919-23-7

4240 441336

Titanium dioxide

Approved

Phase 4

13463-67-7

Raltitrexed

Approved, Investigational

Phase 4

112887-68-0

104758 135400182

Mitomycin

Approved

Phase 4

50-07-7

5746

Anti-Allergic Agents

Phase 4

Anti-Bacterial Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Dapsone

Approved, Investigational

Phase 3

80-08-0

2955

Minocycline

Approved, Investigational

Phase 3

10118-90-8, 13614-98-7

54675783 5281021

Cobalt

Approved, Experimental, Withdrawn

Phase 3

7440-48-4

104729

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Gefitinib

Approved, Investigational

Phase 3

184475-35-2

123631

Sodium citrate

Approved, Investigational

Phase 2, Phase 3

68-04-2

23431961

Palbociclib

Approved, Investigational

Phase 3

571190-30-2

5330286

Atezolizumab

Approved, Investigational

Phase 3

1380723-44-3

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 3

62-33-9, 60-00-4

6049

Pentetic acid

Approved

Phase 3

67-43-6

Melatonin

Approved, Nutraceutical, Vet_approved

Phase 3

73-31-4

896

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 2, Phase 3

77-92-9

311

Kava

Approved, Investigational, Nutraceutical

Phase 3

9000-38-8

Zalutumumab

Investigational

Phase 3

667901-13-5

Tirapazamine

Investigational

Phase 3

27314-97-2

135413511

Nimorazole

Investigational

Phase 3

6506-37-2

23009

Endostatins

Phase 3

Antirheumatic Agents

Phase 3

1,2-diaminocyclohexaneplatinum II citrate

Phase 2, Phase 3

Citrate

Phase 2, Phase 3

Lugol's solution

Phase 3

Anti-Infective Agents

Phase 3

Chelating Agents

Phase 3

Antiprotozoal Agents

Phase 3

Antiparasitic Agents

Phase 3

Radiopharmaceuticals

Phase 3

Anticoagulants

Phase 3

Blood Substitutes

Phase 3

Plasma Substitutes

Phase 3

Technetium Tc 99m Pentetate

Phase 3

Dextrans

Phase 3

Orange

Approved

Phase 2

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Axitinib

Approved, Investigational

Phase 2

319460-85-0

6450551

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Metformin

Approved

Phase 1, Phase 2

1115-70-4, 657-24-9

4091

Acetylcysteine

Approved, Investigational

Phase 2

616-91-1

581 12035

Romidepsin

Approved, Investigational

Phase 2

128517-07-7

5352062

Bortezomib

Approved, Investigational

Phase 2

179324-69-7

387447 93860

Acalabrutinib

Approved, Investigational

Phase 2

1420477-60-6

71226663 71226662

Interventional clinical trials:

(show top 50) (show all 1129)

#	Name	Status	NCT ID	Phase	Drugs
1	A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor	Unknown status	NCT04766827	Phase 4	albumin-bound paclitaxel
2	Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy	Unknown status	NCT02495064	Phase 4	Mometasone Furoate Cream
3	Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer	Completed	NCT03998696	Phase 4	Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
4	Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors	Completed	NCT01344356	Phase 4
5	Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial	Recruiting	NCT03196843	Phase 4	Raltitrexed
6	A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10).	Active, not recruiting	NCT04489888	Phase 4	Pembrolizumab;Carboplatin;Paclitaxel
7	Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck	Terminated	NCT02015650	Phase 4	Cetuximab;Mitomycin-C/ 5-Fluorouracil
8	Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx	Withdrawn	NCT03388931	Phase 4
9	SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial	Unknown status	NCT04146402	Phase 3	SCT-I10A+chemo;Placebos+chemo
10	Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma	Unknown status	NCT01874171	Phase 3	Cisplatin;Cetuximab
11	Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy（Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ） Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma（R/M SCCHN）	Unknown status	NCT03855384	Phase 3	TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
12	A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region	Unknown status	NCT02630264	Phase 3	Endostatins;Paclitaxel injection;Cisplatin injection
13	Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin	Unknown status	NCT00999700	Phase 3	docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin
14	Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial	Unknown status	NCT02923258	Phase 2, Phase 3	Docetaxel;Cisplatinum
15	A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT	Completed	NCT01931150	Phase 3	Topical Dapsone 5% Gel;oral antibiotics
16	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients	Completed	NCT02551159	Phase 3	5-fluorouracil (5FU);Cisplatin;Carboplatin
17	Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma	Completed	NCT01864850	Phase 3
18	Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC)	Completed	NCT04137627	Phase 3	Melatonin 20 MG Oral Capsule;Placebo oral capsule
19	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Completed	NCT02741570	Phase 3	Cetuximab/Erbitux;Cisplatin/Platinol;Carboplatin/Paraplatin;Fluorouracil/Adrucil
20	Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb)	Completed	NCT02715596	Phase 3
21	Phase III Randomized Comparison of Radiotherapy Fractionation in Advanced Squamous Cell Carcinoma of the Head and Neck: Twice-Daily Hyperfractionation vs Split-Course Accelerated Hyperfractionation vs Accelerated Fractionation With Concomitant Boost vs Standard Fractionation	Completed	NCT00771641	Phase 3
22	An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Completed	NCT02105636	Phase 3	Nivolumab;Cetuximab;Methotrexate;Docetaxel
23	A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)	Completed	NCT01950689	Phase 3	Nimorazole
24	Phase I/II Trial of Erlotinib, Radiation Therapy, and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00442455	Phase 3	Erlotinib chlorhydrate;Cisplatin
25	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Completed	NCT03349710	Phase 3	Cetuximab;Cisplatin
26	DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00496652	Phase 3	Zalutumumab
27	Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma	Completed	NCT00158652	Phase 3	5FU, Paraplatin
28	Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00122460	Phase 3	Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU);Platinum (Cisplatin or Carboplatin) + 5-FU
29	Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study.	Completed	NCT01086826	Phase 3	RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
30	A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma	Completed	NCT00162708	Phase 2, Phase 3	CDDP, 5 Fu
31	Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer	Completed	NCT00174837	Phase 3	Tirapazamine;Cisplatin
32	Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety of Cetuximab When Given in Combination With Radiotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects	Completed	NCT01012258	Phase 3
33	A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck	Completed	NCT02383966	Phase 3	Cetuximab;Cisplatin/Carboplatin;5-fluorouracil
34	Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients	Completed	NCT00201279	Phase 3	13-cis Retino Acid
35	A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00206219	Phase 3	Gefitinib;methotrexate
36	Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients	Completed	NCT00201383	Phase 3	cisplatin
37	An Open-label, Randomized, Parallel-group, Multicenter Study of Neoadjuvant Docetaxel(Taxotere®) Plus Cisplatin Plus 5-fluorouracil Versus Neoadjuvant Cisplatin Plus 5-fluorouracil in Patients With Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00995293	Phase 3	DOCETAXEL;CISPLATIN;5-FLUOROURACIL
38	A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Completed	NCT02369874	Phase 3	MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
39	Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy	Completed	NCT02347332	Phase 3	Vinflunine;Methotrexate
40	Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux	Completed	NCT00609284	Phase 3	cetuximab;Carboplatin, 5FU concomitant
41	Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma	Completed	NCT01542931	Phase 2, Phase 3	TPF induction chemotherapy
42	A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02	Completed	NCT01427478	Phase 3	AFATINIB;Placebo of AFATINIB
43	Open-label, Single-arm, Multicenter, Phase III Trial to Assess the Antitumor Activity and Safety Profile of Cetuximab When Given in Combination With Chemotherapy for the First-line Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck in Asian Subjects	Completed	NCT01177956	Phase 3	Cisplatin;5-Fluorouracil
44	Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck	Recruiting	NCT01810913	Phase 2, Phase 3	Atezolizumab;Cisplatin;Docetaxel
45	A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers	Recruiting	NCT05063552	Phase 2, Phase 3	Carboplatin;Cisplatin;Docetaxel
46	Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Recruiting	NCT05050162	Phase 2, Phase 3	Cisplatin
47	A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma	Recruiting	NCT03815903	Phase 3	Induction chemotherapy
48	Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer	Recruiting	NCT04333537	Phase 2, Phase 3	Imaging Agent
49	A Phase 3, Prospective，Multicenter, Randomized Open-Label Trial to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Chemotherapy Followed By Surgery Versus Up-Front Surgery as Treatment for Resectable Head And Neck Squamous Cell Carcinoma	Recruiting	NCT05582265	Phase 3	Tislelizumab（neoadjuvant）;Cisplatin （neoadjuvant）;Nab-paclitaxel （neoadjuvant）;Cisplatin（adjuvant）;Tislelizumab（adjuvant）
50	Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck	Recruiting	NCT01893307	Phase 2, Phase 3

Search NIH Clinical Center for Laryngeal Squamous Cell Carcinoma

Cochrane evidence based reviews: squamous cell carcinoma of head and neck

Sources

Genetic Tests for Laryngeal Squamous Cell Carcinoma

Sources

Anatomical Context for Laryngeal Squamous Cell Carcinoma

Organs/tissues related to Laryngeal Squamous Cell Carcinoma:

MalaCards : Lung, Lymph Node, Liver, T Cells, Myeloid, Salivary Gland, Breast

Sources

Publications for Laryngeal Squamous Cell Carcinoma

Articles related to Laryngeal Squamous Cell Carcinoma:

(show top 50) (show all 3181)

#	Title	Authors	PMID	Year
1	GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. ⁵³ ⁶²	Chatzimichalis M...Bibas A	19922706	2010
2	Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Zou J...Liu S	19741544	2010
3	Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. ⁵³ ⁶²	Farhadieh RD...Smee R	19669840	2009
4	EGFR immunoexpression and peripheral blood cytokine secretion as potential biomarkers of tumor behavior in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Starska K...Lukomski M	19789511	2009
5	Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. ⁵³ ⁶²	Liao Z...Zhou Y	19375219	2009
6	[Relationships of human laryngeal squamous cell carcinomas with the expression of VEGF-C and VEGFR-3]. ⁵³ ⁶²	Wang Z...Chen Y	19813623	2009
7	[The expressions and correlation of AQP1 and VEGF in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Gao X...Liu J	19670620	2009
8	Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Starska K...Lukomski M	19148533	2009
9	[The expression of Galectin-3 and VEGF in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Kong H...Dong Z	19452726	2009
10	p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. ⁵³ ⁶²	Jiang H...Yang BB	18607952	2009
11	Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. ⁵³ ⁶²	Farhadieh RD...Russell PJ	19183379	2009
12	Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. ⁵³ ⁶²	Bang CI...Kim MS	18998509	2008
13	[hTERT promoter enhances the radiosensitivity to gene-radiation therapy of human laryngeal carcinoma transplanted in nude mice]. ⁵³ ⁶²	Huang CH...Zhou YF	19173799	2008
14	[Effect of CDK2 on proliferation in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Zhang H...Huangfu H	19166026	2008
15	[Study of the lymph node micrometastasis in patients with supraglottic carcinoma]. ⁵³ ⁶²	Zhao J...Liu D	19166031	2008
16	[Expression of angiopoietin-1,2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Xu G...Zhang P	19086654	2008
17	Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Swellam M...Adly A	18602381	2008
18	[Detection of Skp2 mRNA gene expression using fluorogenic probe quantitative RT-PCR method in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Guo J...Hu B	18800682	2008
19	Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. ⁵³ ⁶²	Micozkadioglu D...Cinel L	18509272	2008
20	Short hairpin ribonucleic acid targeting the telomerase catalytic unit of messenger ribonucleic acid significantly limits the growth of laryngeal squamous cell carcinoma in nude mice. ⁵³ ⁶²	Zhou XH...Tao ZZ	17592663	2008
21	Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis. ⁵³ ⁶²	Kitamura K...Suzuki M	18357366	2008
22	[Expression of cyclin G1 in laryngeal squamous cell carcinoma and its clinicopathologic significance]. ⁵³ ⁶²	Cui XF...Chen XG	18788592	2008
23	[Expression of Survivin, Caspase-3 and p53 in surgical margin of laryngeal squamous cell carcinoma and their relationship]. ⁵³ ⁶²	Du J...Su Y	18476631	2008
24	Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. ⁵³ ⁶²	Fu ZJ...Pan XL	18787961	2008
25	Possible prognostic role of p53 expression in laryngeal squamous cell carcinoma of non-smokers, non-alcoholic patients. ⁵³ ⁶²	Fernandez-Acenero MJ...Ortega P	18607961	2008
26	Expression of PTEN protein in patients with laryngeal squamous cell carcinoma. ⁵³ ⁶²	Guney K...Cetin S	17475427	2007
27	[Effects of HPV 16-E6/E7 oncogene on expression of vascular endothelial growth factor and matrix metalloproteinase 9 in human laryngeal squamous cell carcinoma cell line]. ⁵³ ⁶²	Cai P...Li JR	18307884	2007
28	Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. ⁵³ ⁶²	Guan Z...Liu Q	17974987	2007
29	Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. ⁵³ ⁶²	Shigyo H...Harabuchi Y	17712678	2007
30	[Expression and clinical significance of Endostatin, vascular endothelial growth factor and fibroblast growth factor basic-2 in laryngeal carcinoma]. ⁵³ ⁶²	Liu WW...Sun QF	18051571	2007
31	[Expression and role of survivin in laryngeal squamous cell carcinoma and laryngeal papilloma in adults]. ⁵³ ⁶²	Xie H...Song F	17634026	2007
32	Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC). ⁵³ ⁶²	Xian J...Liu S	17328665	2007
33	[Clinical significance and expression of FLIP and PTEN protein in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Wei Z...Zhou X	17441421	2007
34	The role of host immune response and apoptosis in patients with laryngeal squamous cell carcinoma. ⁵³ ⁶²	Gomatos IP...Ferekidou E	17264532	2007
35	[Expression and clinical significance of matrix metalloproteinase-2 in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Wang X...Luo S	17357514	2006
36	[Expression of telomerase reverse transcriptase and its relationship with expression of c-myc in laryngeal squamous cell carcinomas]. ⁵³ ⁶²	Chen Z...Jiang M	17219990	2006
37	5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. ⁵³ ⁶²	Liu HC...van Hasselt CA	17207318	2006
38	Expression of the apoptosis inhibitor protein Survivin in primary laryngeal carcinoma and cervical lymph node metastasis. ⁵³ ⁶²	Marioni G...Staffieri A	17094406	2006
39	Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. ⁵³ ⁶²	Acar H...Ozer B	16938565	2006
40	Immunohistochemical estimation of cell cycle phase in laryngeal neoplasia. ⁵³ ⁶²	Chatrath P...Coleman N	16832409	2006
41	[Construction of recombinant adenovirus vector carrying cell cycle controlling gene-p14ARF]. ⁵³ ⁶²	Xian JM...Liu SX	16845966	2006
42	[The investigation of STK15 gene amplification and overexpression in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Ye Y...Sun KL	16767676	2006
43	[The relationship between hypermethylation of the PTEN promoter and laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Bai W...Wang T	16739377	2006
44	[The clinical significance of the expression of p63 gene in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Jia H...Hou J	16646404	2006
45	Expression of vascular endothelial growth factor and cyclooxygenase-2 in laryngeal squamous cell carcinoma and its significance. ⁵³ ⁶²	Chen G...Gong S	16711020	2006
46	TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Russo A...Bazan V	15965904	2006
47	Promoter hypermethylation of DNA repair gene MGMT in laryngeal squamous cell carcinoma. ⁵³ ⁶²	Zhang S...Liu Z	16711019	2006
48	[Inhibitory effect of silencing hTERT gene by short hairpin RNA on growth of human laryngeal squamous cell carcinoma xenograft in nude mice]. ⁵³ ⁶²	Liu D...Chi HM	16405742	2006
49	Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. ⁵³ ⁶²	Gorogh T...Maune S	16265652	2006
50	[The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma]. ⁵³ ⁶²	Yaylaci A...Gokceer T	16763427	2006

Sources

Genes for Laryngeal Squamous Cell Carcinoma

Genes related to Laryngeal Squamous Cell Carcinoma (3 elite genes):

(show top 50) (show all 82)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PTEN	Phosphatase And Tensin Homolog	Protein Coding	369.92	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11801303 16739377 17441421 (more) 15831044 16075977 17357516 15127561 17475427 14720383
2	ING1	Inhibitor Of Growth Family Member 1	Protein Coding	350	Causative somatic mutation ⁵⁸	10866301
3	TNFRSF10B	TNF Receptor Superfamily Member 10b	Protein Coding	28.47	Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴	9721831
4	MIR21	MicroRNA 21	RNA Gene	159.65	Experimental evidence ³⁷ DISEASES inferred ¹⁴ ¹⁴	25099764
5	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	156.54	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	23141928 24817925 25099764 (more) 25257554 27542077
6	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	155.89	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26822763
7	HOXA11-AS	HOXA11 Antisense RNA	RNA Gene	155.37	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	29511452
8	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	155.23	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25257554
9	LINC01537	Long Intergenic Non-Protein Coding RNA 1537	RNA Gene	155.22	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25243407
10	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	155.15	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	28631575
11	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	153.97	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	24817925 25257554
12	RRP1B	Ribosomal RNA Processing 1B	Protein Coding	152.89	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	25257554
13	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	150	Experimental evidence: Regulation ³⁷	26872375
14	MTCO1P5	MT-CO1 Pseudogene 5	Pseudogene	150	Experimental evidence: Regulation ³⁷	25243407
15	SRA1	Steroid Receptor RNA Activator 1	Protein Coding	150	Experimental evidence: Regulation ³⁷	25257554
16	TP53	Tumor Protein P53	Protein Coding	24.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9294474 18607961 12526287 (more) 15023836 9515767 8803594 10368653 11131662 18788592 14995078 9868114 18476631 15965904 11829192 12545812 19582341 17207318 16398049 15279637 15199601 7850072 16340285 12642632 11320623 9267820 12514403 18607952 12883724 11520092 10875157 9281367 10323025 7829392 16739381 15663083 11012985 10562812 9563667 7599785 18357366 16763427 11956639 11836691 12600081 10942137 10448265 9950162 19183379 11400228 8762527 7882279 12561442 11016683 8639294 14681317 7788934 18509272 12761985 12761983 9610695 10419041 10191626 14690561
17	CCND1	Cyclin D1	Protein Coding	22.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12563983 17139501 9829720 (more) 11400112 16832409 12669430 16327270 19681484 9816104 16116829
18	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15071918 10323033 12778765 (more) 12768709 18787961 12812651 16845966 15473298 12761983 10194257 18602381 12761910 18357366 11836682 16760277
19	EGFR	Epidermal Growth Factor Receptor	Protein Coding	22.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9644164 11751491 9271009 (more) 18607952 19669840 15473298 17328665 19789511 8883413 1442018 1991297 12669431 19148533 8667988 10435153 12541423 11668514 14649542 10096253 7793243 15848906 10191626
20	BCL2	BCL2 Apoptosis Regulator	Protein Coding	21.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12526287 10368653 11520092 (more) 12740649 16013505 10091732 11829192 12883724 11320623 9610695 11012985 16675913 11400228 17264532 10942137 12600081 10448265 10419041
21	AURKA	Aurora Kinase A	Protein Coding	20.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12812651 16767676 17974987 (more) 12693093 16377583 15192826
22	CDH1	Cadherin 1	Protein Coding	20.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19741544 9816133 10609562 (more) 16941960 16259108 15848906 16404343 11956639
23	TERT	Telomerase Reverse Transcriptase	Protein Coding	20.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17592663 17219990 15823813 (more) 11911285 16405742 19173799 19375219 16739381
24	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	20.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15510660 10782883 16124648 (more) 16711020 15362688 19670620 19452726 16408728 19086654 11843932 18307884 16763427 17712678 15831042 18051571 9426404
25	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	19.69	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8635091 9642340 12014221 (more) 11189167 9555115
26	BIRC5	Baculoviral IAP Repeat Containing 5	Protein Coding	19.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18998509 12174930 15279637 (more) 16375115 16176004 18476631 15566665 16013505 17634026 15191673 16075977 17094406
27	SKP2	S-Phase Kinase Associated Protein 2	Protein Coding	19.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12579266 16075976 19961778 (more) 18800682
28	GSTM3	Glutathione S-Transferase Mu 3	Protein Coding	19.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19922706
29	MMP2	Matrix Metallopeptidase 2	Protein Coding	19.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15746850 17357514 17341208 (more) 14729463 9555115 16265652
30	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	18.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15473298 12812651 18602381 (more) 11836682
31	MKI67	Marker Of Proliferation Ki-67	Protein Coding	18.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10824607 10419041 12649825 (more) 10435153 10628385 16340285
32	CCNB1	Cyclin B1	Protein Coding	18.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11809526 16832409
33	MCM2	Minichromosome Maintenance Complex Component 2	Protein Coding	17.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16832409 12966424
34	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	17.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15522186 16013507 15906520 (more) 18357366
35	CDK2	Cyclin Dependent Kinase 2	Protein Coding	16.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19166026 11299721
36	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	16.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16938565 15914211 19922706
37	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	16.51	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15844604 12740649 16995968 (more) 18607952 9097710 15199601 10824607 8762515 12378803 11410133 8745457 16512489 10435153 10684010 11400112 15791865 18509272 9816133 9624390
38	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	16.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10368653 11320623 10091732 (more) 11520092 17264532 10942137 10419041 12883724
39	KRT19	Keratin 19	Protein Coding	16.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19166031
40	EIF4E	Eukaryotic Translation Initiation Factor 4E	Protein Coding	16.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12838026 16124648 15510630 (more) 12889116
41	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	15.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10506612 10562812
42	CTSD	Cathepsin D	Protein Coding	15.78	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8962695 11820719 10850757 (more) 11012985 12528259
43	MMP1	Matrix Metallopeptidase 1	Protein Coding	15.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12739032 16265652 9758368
44	TP63	Tumor Protein P63	Protein Coding	15.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16375115 12379767 16646404
45	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	15.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10355825
46	CCND3	Cyclin D3	Protein Coding	15.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15671552
47	CYP2E1	Cytochrome P450 Family 2 Subfamily E Member 1	Protein Coding	15.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15914211
48	CYP1A1	Cytochrome P450 Family 1 Subfamily A Member 1	Protein Coding	14.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15914211 14639127
49	IFI27	Interferon Alpha Inducible Protein 27	Protein Coding	14.61	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12669430 16116829 15742257 (more) 10334237 10506612 11410133
50	TP73	Tumor Protein P73	Protein Coding	14.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14720383 11323391 16512489

Sources

Variations for Laryngeal Squamous Cell Carcinoma

Sources

Expression for Laryngeal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Laryngeal Squamous Cell Carcinoma.

Sources

Pathways for Laryngeal Squamous Cell Carcinoma

Pathways related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 28)

#	Super pathways	Score	Top Affiliating Genes
1	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.82	BCL2 CDKN2A EGFR PTEN TNFRSF10B TP53
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.55	TP53 PTEN EGFR CDKN2A CCND1 BCL2
3	Malignant pleural mesothelioma ⁷⁴	12.52	TP53 PTEN EGFR CDKN2A CCND1 BCL2
4	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.37	TP53 PTEN CCND1 BCL2
5	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.36	TP53 PTEN EGFR CCND1
6	Focal adhesion ⁷⁴	12.2	PTEN EGFR CCND1 BCL2
7	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.12	TP53 PTEN EGFR CCND1 BCL2
8	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.06	TP53 PTEN CDKN2A CCND1
9	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12	BCL2 CCND1 PTEN TNFRSF10B TP53
10	Integrated breast cancer pathway ⁷⁴	11.9	TP53 PTEN EGFR CCND1 BCL2
11	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.85	TP53 CCND1 BCL2
12	DNA damage response (only ATM dependent) ⁷⁴	11.83	BCL2 CCND1 PTEN TP53
13	Small cell lung cancer ⁷⁴	11.79	TP53 PTEN CCND1 BCL2
14	Direct p53 effectors ⁶¹	11.76	TP53 TNFRSF10B PTEN EGFR BCL2
15	C-MYB transcription factor network ⁶¹	11.7	CDKN2A CCND1 BCL2
16	miRNAs involved in DNA damage response ⁷⁴	11.62	TP53 MIR21 CCND1
17	Prader-Willi and Angelman syndrome ⁷⁴	11.57	TP53 CDKN2A CCND1
18	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.54	TP53 PTEN CCND1
19	AP-1 transcription factor network ⁶¹	11.54	TP53 PTEN CDKN2A CCND1
20	Senescence and autophagy in cancer ⁷⁴	11.37	TP53 PTEN ING1 CDKN2A BCL2
21	Inhibition of Signaling by Overexpressed EGFR ⁶⁶ Show member pathways Estrogen-dependent nuclear events downstream of ESR-membrane signaling ⁶⁶ Signaling by Overexpressed Wild-Type EGFR in Cancer ⁶⁶	11.35	EGFR CCND1 BCL2
22	Integrated cancer pathway ⁷⁴	11.31	TP53 PTEN BCL2
23	miRNA regulation of p53 pathway in prostate cancer ⁷⁴	11.23	TP53 TNFRSF10B PTEN
24	Bladder cancer ⁷⁴	11.06	TP53 EGFR CDKN2A CCND1
25	Unfolded protein response ⁷⁴	11.01	TP53 TNFRSF10B BCL2
26	TP53 network ⁷⁴ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.95	TP53 CDKN2A BCL2
27	Head and neck squamous cell carcinoma ⁷⁴	10.88	TP53 PTEN EGFR CDKN2A CCND1
28	MicroRNA network associated with chronic lymphocytic leukemia ⁷⁴	10.36	TP53 BCL2

Sources

GO Terms for Laryngeal Squamous Cell Carcinoma

Biological processes related to Laryngeal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	10.21	BCL2 CDKN2A PTEN RRP1B SRA1 TNFRSF10B
2	negative regulation of cell population proliferation	GO:0008285	10.1	TP53 PTEN MIR21 ING1 CDKN2A BCL2
3	negative regulation of cell growth	GO:0030308	10.06	TP53 ING1 CDKN2A BCL2
4	regulation of cell cycle	GO:0051726	10.05	TP53 PTEN CDKN2A CCND1 BCL2
5	cellular response to hypoxia	GO:0071456	10.02	TP53 PTEN MALAT1 BCL2
6	intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	GO:0070059	9.85	TP53 TNFRSF10B BCL2
7	B cell lineage commitment	GO:0002326	9.8	TP53 BCL2
8	T cell lineage commitment	GO:0002360	9.7	TP53 BCL2
9	positive regulation of apoptotic process	GO:0043065	9.65	TP53 TNFRSF10B RRP1B MIR21 CDKN2A BCL2
10	response to UV-A	GO:0070141	9.62	CCND1 EGFR
11	cell population proliferation	GO:0008283	9.55	TP53 PTEN EGFR CCND1 BCL2
12	positive regulation of miRNA maturation	GO:1903800	9.54	TP53 EGFR
13	negative regulation of mitotic cell cycle	GO:0045930	9.43	TP53 MIR21 BCL2
14	negative regulation of superoxide dismutase activity	GO:1901670	8.62	MIR21 H19